SecBot SecBot
Biotech Drug Report Generated Oct 26, 2026

PDS0103

PDSB·PDS Biotechnology Corp
BEARISH
Drug Impact Rating1/10
Trial phase
Preclinical (IND cleared for Phase 1/2)
Time to market
Unknown, the drug is in late-stage preclinical development with an IND cleared for an NCI-led Phase 1/2 trial. Even if the trial begins soon, clinical development typically takes 5+ years for a novel immunotherapy.
Why 1/10
No hard, dated catalyst is scheduled for PDS0103 in the next ~12 months. The drug is preclinical/IND-stage, the company has deprioritized it in favor of PDS0301, and the NCI-led Phase 1/2 trial has no publicly announced enrollment or data-readout timeline. ImpactScore is 1 because PDS0103 is a very early-stage, deprioritized program at a cash-constrained company with no near-term binary event.
Actionable Insight BEARISH

PDS0103 is a preclinical/IND-stage asset that has been deprioritized by PDS Biotech in favor of PDS0301. The NCI-led Phase 1/2 trial could begin enrollment at any time, but the company has no near-term catalyst for this drug and is actively seeking a partner for the Versamune platform. Watch for partnership announcements or NCI trial initiation as potential value-unlocking events, but the stock's near-term trajectory depends almost entirely on PDS0301 developments.

Price Chart

Loading chart...

Executive Summary

PDS0103 (Versamune MUC1) is an early-stage, preclinical cancer immunotherapy from PDS Biotechnology Corp (Nasdaq: PDSB) that targets MUC1-positive solid tumors. The FDA cleared an IND in March 2025 for an NCI-led Phase 1/2 trial in metastatic colorectal cancer, but no human data or enrollment updates have been reported. In August 2026, PDS Biotech announced a strategic refocus prioritizing PDS0301 (an IL-12 immunocytokine) and stated it would seek partnerships for the Versamune platform, meaning PDS0103 is now a deprioritized, non-core asset at a company with only ~$5.6M in cash. With no near-term catalysts and no clinical data, PDS0103 is a very minor component of PDSB's investment thesis.

How It Works

PDS0103 is a cancer vaccine that trains the body's immune system to recognize and attack cells displaying a protein called MUC1, which is found on the surface of many solid tumors (including breast, ovarian, colorectal, and lung cancers). It uses PDS Biotech's Versamune® platform, a synthetic molecule that activates T cells (the immune system's killer cells), combined with MUC1 protein fragments designed by the National Cancer Institute. The drug is given as a simple shot under the skin.

Trial Status

PDS0103 is in late-stage preclinical development. The FDA cleared an IND application in March 2025 for a Phase 1/2 trial evaluating PDS0103 (Versamune MUC1) in combination with PDS01ADC for metastatic colorectal cancer, to be conducted by the National Cancer Institute under a CRADA. No enrollment or data updates have been announced as of October 2026.

The Two-Sided Case

▲ Bull Case4
PDS0103 targets MUC1, which is overexpressed in multiple solid tumors (ovarian, breast, colorectal, lung), a large addressable market if successful.
The IND was cleared by the FDA in March 2025, and the NCI is leading the Phase 1/2 trial under an existing CRADA, a strong validation and cost-efficient development path for PDS Biotech.
The Versamune platform has shown encouraging clinical data in other programs (PDS0101 achieved 39.3-month median OS in HPV16-positive head and neck cancer), providing some technology de-risking.
If PDS Biotech secures a partnership for the Versamune platform (as stated in its strategic refocus), PDS0103 could advance with non-dilutive funding.
▼ Bear Case5
PDS0103 is only in late-stage preclinical development with no human clinical data yet, a very early, high-risk stage.
The company (PDSB) has explicitly deprioritized the entire Versamune platform (including PDS0103) to focus resources on PDS0301, per the August 2026 strategic refocus.
PDS Biotech had only $5.6M in cash as of Q2 2026, raising serious questions about how any Versamune program (including PDS0103) gets funded without a partner.
The NCI-led Phase 1/2 trial has been cleared by the FDA (March 2025) but no enrollment update has been provided, suggesting slow progress.
MUC1 is a well-known but difficult oncology target, multiple prior MUC1-directed therapies have failed in the clinic.

Upcoming Catalysts

  • Potential initiation of NCI-led Phase 1/2 trial (no timeline announced)
  • Possible Versamune platform partnership announcement (company seeking external funding for all Versamune assets)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PDS Biotechnology Corp 8-K PDSB ·Originating report

Sources · 9

Hover a chip for the title
1 pdsbiotech.com2 pdsbiotech.com3 pdsbiotech.com4 biospace.com5 pdsbiotech.com6 synapse.patsnap.com7 pdsbiotech.com8 pdsbiotech.com9 sec.gov